We are live on ! Find out more
ITRM

Iterum Therapeutics
ITRM

Delisted

ITRM was delisted on the 31st of March, 2026.

Back to rankings

17 hedge funds and large institutions have $187K invested in Iterum Therapeutics in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

0.42% less ownership

Funds ownership: 1.89% → 1.47% (-0.42%)

5% less capital invested

Capital invested by funds: $198K → $187K (-$10.4K)

23% less funds holding

Funds holding: 22 → 17 (-5)

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

Holders
17
Holders Change
-5
Holders Change %
-22.73%
% of All Funds
0%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
2
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$6.29K
2
TRCT
Tower Research Capital (TRC)
New York
+$6.07K
3
Renaissance Technologies
Renaissance Technologies
New York
+$2.08K
4
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management
Wisconsin
+$153

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$20K
2
UBS Group
UBS Group
Switzerland
-$17.6K
3
Franklin Resources
Franklin Resources
California
-$14.6K
4
IA
IFP Advisors
Florida
-$3K
5
FWM
Focused Wealth Management
New York
-$384

ITRM Hedge Fund Activity: Q1 2023 in Review

17 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q1 2023, worth a combined $187K — down 5.3% from $198K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ITRM and 1 opened new positions — a net loss of 5 holders — while 2 trimmed existing stakes and 3 added.

The largest buyer was Morgan Stanley, adding an estimated $6.29K. The largest seller was Virtu Financial, exiting entirely with an estimated $20K sold.

  • 17 institutional investors held Iterum Therapeutics (ITRM) as of Q1 2023, down from 22 in Q4 2022.
  • Funds reported $187K of Iterum Therapeutics stock for Q1 2023, down 5.3% quarter-over-quarter.
  • 1 fund opened new Iterum Therapeutics positions in Q1 2023 and 6 closed out, a net change of -5 holders.
  • The largest Iterum Therapeutics buyer in Q1 2023 was Morgan Stanley, an estimated $6.29K added.
  • The largest Iterum Therapeutics seller in Q1 2023 was Virtu Financial, an estimated $20K sold.

Based on aggregated 13F filings for Q1 2023.